CL2011000237A1 - Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico. - Google Patents

Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico.

Info

Publication number
CL2011000237A1
CL2011000237A1 CL2011000237A CL2011000237A CL2011000237A1 CL 2011000237 A1 CL2011000237 A1 CL 2011000237A1 CL 2011000237 A CL2011000237 A CL 2011000237A CL 2011000237 A CL2011000237 A CL 2011000237A CL 2011000237 A1 CL2011000237 A1 CL 2011000237A1
Authority
CL
Chile
Prior art keywords
epiridine
labeling
pet
derivatives
pharmaceutical composition
Prior art date
Application number
CL2011000237A
Other languages
English (en)
Inventor
Lutz Lehmann
Andrea Thiele
Tobias Henrich
Sonja Vollmer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CL2011000237A1 publication Critical patent/CL2011000237A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos derivados de 3-piridin-amidas sustituidas; composición farmacéutica; kit farmacéutico; procedimiento de preparación; útiles en el diagnóstico de enfermedades del SNC.
CL2011000237A 2008-08-06 2011-02-04 Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico. CL2011000237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161903 2008-08-06

Publications (1)

Publication Number Publication Date
CL2011000237A1 true CL2011000237A1 (es) 2011-07-29

Family

ID=41198601

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000237A CL2011000237A1 (es) 2008-08-06 2011-02-04 Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico.

Country Status (24)

Country Link
US (1) US20110200535A1 (es)
EP (1) EP2321279B1 (es)
JP (1) JP2011529929A (es)
KR (1) KR20110041559A (es)
CN (1) CN102112448B (es)
AR (1) AR073263A1 (es)
AU (1) AU2009278279B2 (es)
BR (1) BRPI0917099A2 (es)
CA (1) CA2733105A1 (es)
CL (1) CL2011000237A1 (es)
CO (1) CO6351715A2 (es)
CR (1) CR20110064A (es)
DO (1) DOP2011000046A (es)
EA (1) EA018650B1 (es)
EC (1) ECSP11010808A (es)
IL (1) IL210597A0 (es)
MX (1) MX2011001406A (es)
NZ (1) NZ590923A (es)
PE (1) PE20110226A1 (es)
SV (1) SV2011003830A (es)
TW (1) TW201010734A (es)
UY (1) UY32037A (es)
WO (2) WO2010015340A1 (es)
ZA (1) ZA201101700B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2405655T3 (es) 2006-12-26 2013-05-31 Lantheus Medical Imaging, Inc. N-[3-bromo-4-(3-[18F]fluoropropoxi)-bencil]-guanidina para la formación de imágenes de la inervación cardíaca
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
GB0904715D0 (en) * 2009-03-19 2009-05-06 Ge Healthcare Ltd Aryloxyanilide derivataives
WO2011110488A1 (en) * 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft A novel pet imaging agent of amyloid plaques and its precursor
ES2763815T3 (es) 2010-05-11 2020-06-01 Lantheus Medical Imaging Inc Composiciones, métodos y sistemas para la síntesis y uso de agentes de formación de imágenes
EP2571875A4 (en) 2010-05-14 2013-10-30 Dana Farber Cancer Inst Inc CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CN108484449A (zh) 2011-09-09 2018-09-04 蓝瑟斯医学影像公司 用于合成和使用显像剂的组合物、方法和系统
US9975896B2 (en) 2013-07-25 2018-05-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
JP2017506666A (ja) 2014-02-28 2017-03-09 テンシャ セラピューティクス，インコーポレイテッド 高インスリン血症に関連した症状の処置
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
CN106793775B (zh) 2014-08-08 2020-06-02 达纳-法伯癌症研究所股份有限公司 二氢碟啶酮衍生物及其用途
KR20170068597A (ko) 2014-10-27 2017-06-19 텐샤 세러퓨틱스 인코포레이티드 브로모도메인 저해제
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
EP3347021A4 (en) 2015-09-11 2019-07-24 Dana-Farber Cancer Institute, Inc. CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
CN105541931B (zh) * 2016-01-07 2018-08-17 江西师范大学 一种氟代糖苷衍生物及其制备方法
EA202091323A1 (ru) * 2017-12-01 2020-10-09 Юсб Байофарма Срл Визуализирующие средства
CN111039853B (zh) * 2019-12-26 2023-02-14 安徽大学 一种可用于光声成像和光热治疗的铁配合物及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333358B1 (en) * 1997-08-04 2001-12-25 Taisho Pharmaceutical Co., Ltd. Aryloxyaniline derivatives
JP2000001476A (ja) * 1998-06-15 2000-01-07 Taisho Pharmaceut Co Ltd アリールオキシ含窒素アリールアミン誘導体
JP2004231647A (ja) * 2003-01-10 2004-08-19 Natl Inst Of Radiological Sciences フェニルオキシアニリン誘導体
US6870069B2 (en) * 2003-01-10 2005-03-22 National Institute Of Radiological Sciences Phenyloxyaniline derivatives
GB0329716D0 (en) * 2003-12-23 2004-01-28 Amersham Plc Radical trap
GB0407952D0 (en) * 2004-04-08 2004-05-12 Amersham Plc Fluoridation method
US8644910B2 (en) * 2005-07-19 2014-02-04 Biosensors International Group, Ltd. Imaging protocols
US20080293969A1 (en) * 2005-11-22 2008-11-27 Ge Healthcare Limited 18F-Labeled Daa Analogues and Method of Labeling These Analogues as Positron Emission Tomography (Pet) Tracers For Imaging Peripheral Benzodiazepine Receptors
DE102005055524B4 (de) * 2005-11-22 2013-02-07 BEGO Bremer Goldschlägerei Wilh. Herbst GmbH & Co. KG Verfahren, Vorrichtung und System zur Herstellung eines keramischen Formkörpers
GB0525949D0 (en) * 2005-12-21 2006-02-01 Hammersmith Imanet Ltd Pet radiotracers
CA2654369C (en) * 2006-06-21 2014-10-14 Ge Healthcare Limited Radiopharmaceutical products
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment

Also Published As

Publication number Publication date
NZ590923A (en) 2012-12-21
SV2011003830A (es) 2011-05-20
AU2009278279A1 (en) 2010-02-11
TW201010734A (en) 2010-03-16
WO2010015340A1 (en) 2010-02-11
IL210597A0 (en) 2011-03-31
CA2733105A1 (en) 2010-02-11
MX2011001406A (es) 2011-03-21
PE20110226A1 (es) 2011-04-01
BRPI0917099A2 (pt) 2016-02-16
CN102112448B (zh) 2014-08-06
UY32037A (es) 2010-03-26
CR20110064A (es) 2011-03-30
ECSP11010808A (es) 2011-03-31
DOP2011000046A (es) 2011-02-28
AR073263A1 (es) 2010-10-28
EP2321279A1 (en) 2011-05-18
WO2010015387A1 (en) 2010-02-11
JP2011529929A (ja) 2011-12-15
CO6351715A2 (es) 2011-12-20
US20110200535A1 (en) 2011-08-18
CN102112448A (zh) 2011-06-29
ZA201101700B (en) 2014-08-27
KR20110041559A (ko) 2011-04-21
EA018650B1 (ru) 2013-09-30
AU2009278279B2 (en) 2014-04-17
EA201100301A1 (ru) 2011-12-30
EP2321279B1 (en) 2014-07-02

Similar Documents

Publication Publication Date Title
CL2011000237A1 (es) Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico.
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
CL2009000161A1 (es) Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos.
MX2010010407A (es) Derivados de 4-aminociclohexanos sustituidos.
BRPI0711481A8 (pt) derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens
EA201000774A1 (ru) Ингибиторы бета-лактамазы
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
ECSP13012788A (es) Derivados de biciclo[3,2,1]octilamida y sus usos
CY1112095T1 (el) Υποκατεστημενα σπειροκυκλικα παραγωγα κυκλοεξανιου
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
MX2013012793A (es) Aminoacidos radiomarcados para imagen de diagnostico.
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
MA32622B1 (fr) Derives de carbonate de quinuclidine et composition medicinale les comprenant
UY30349A1 (es) Ligandos del receptor de acetilcolina de tipo nicotinico
BRPI0821450A2 (pt) Derivado (aza) indol substituído na posição 5, proceso para a preparação do mesmo, composto intermediário, e, composição farmacêutica.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CO6341625A2 (es) Derivados de indol como agentes anticáncer
DE602006012694D1 (de) Benzimidazolthiophenverbindungen als plk-modulatoren
AU2010332841A8 (en) Prostate specific membrane antigen inhibitors
CR10703A (es) Derivados de silicio para obtencion de imagenes por tomografia de emision de positrones(pet)
CL2009001238A1 (es) Compuestos derivados de acido l-glutamico marcado con [f-18] y derivados de l-glutamina marcada con [f-18]; procedimiento de preparacion; conjunto de diagnostico por imagenes; composiciones farmaceuticas; y uso para el diagnostico por imagenes de enfermedades tumorales.
MX340487B (es) Compuestos para usarse en la formacion de imagenes, diagnostico y/o tratamiento de enfermedades del sistema nervioso central.